Double Bond Pharmaceutical strengthens the team

Double Bond Pharmaceutical has employed Alisha Gupta, MSc in Biomedicine, to strengthen the team for clinical development of their products. Alisha has recently completed her studies and has already been intensively engaged in entrepreneurship and research and has done an internship in Boston to deepen her knowledge in biomedicine.

"We are looking forward to an intensified work load in our clinical development next year, and are very pleased to expand the team with even more creativity, knowledge, innovation and new energy." - commented Igor Lokot, CEO of Double Bond Pharmaceutical. 

For more info, contact
Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com 

Blog: http://blog.doublebp.com

Follow us on LinkedIn, Facebook and Twitter!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.

Tags: